Physician Characteristics and Variability of Erythropoiesis-Stimulating Agent Use Among Medicare Patients With Cancer

被引:25
作者
Wright, Jason D.
Neugut, Alfred I.
Wilde, Elizabeth T.
Buono, Donna L.
Malin, Jennifer [1 ,2 ]
Tsai, Wei Y.
Hershman, Dawn L. [1 ]
机构
[1] Columbia Univ, Med Ctr, New York, NY 10032 USA
[2] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA
关键词
CLINICAL-PRACTICE GUIDELINES; OFF-LABEL USE; UNITED-STATES; AMERICAN SOCIETY; EORTC GUIDELINES; ANEMIC PATIENTS; BREAST-CANCER; CHEMOTHERAPY; PATTERNS; ONCOLOGY;
D O I
10.1200/JCO.2010.34.5462
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Drugs are usually approved for a specific indication on the basis of randomized trials. However, once approved, these treatments are often used differently than as tested in trials. We performed an analysis to determine the patterns of use of erythropoiesis-stimulating agents (ESAs). Methods We used the Surveillance, Epidemiology, and End Results-Medicare database to identify patients age 65 years or older with breast, lung, or colon cancer diagnosed between 1995 and 2005 who had one ESA and chemotherapy claim. Associations of patient, tumor, and physician-related factors with receipt of ESAs were analyzed. Results Of 21,091 patients analyzed, 5,099 (24.2%) received ESAs for 1 week or less (misuse), and 1,601 (7.6%) received ESAs for more than 14 weeks (prolonged use). Receipt of ESAs while not actively receiving chemotherapy (off label) occurred in 2,876 patients (13.6%). In a multivariable analysis, ESA misuse was associated with MD degree, female sex of physician, and earlier year of medical school graduation. Private practice physicians (odds ratio [OR], 0.78; 95% CI, 0.72 to 0.84) and high-volume physicians (OR, 0.78; 95% CI, 0.72 to 0.85) were less likely to use 1 week or less of ESA treatment. Treatment by high-volume oncologists (OR, 1.33; 95% CI, 1.14 to 1.55) and by oncologists who graduated from US medical schools (OR, 1.26; 95% CI, 1.12 to 1.42) predicted prolonged-duration ESA use, whereas female oncologists (OR, 0.79; 95% CI, 0.68 to 0.93) were less likely to prescribe prolonged ESA treatment. Private practice physicians (OR, 1.18; 95% CI, 1.02 to 1.38) and high-volume providers (OR, 1.58; 95% CI, 1.33 to 1.87) were more likely to prescribe more than 24 weeks of ESA treatment. Conclusion Our study demonstrated widespread variability in the use of ESAs. Physician characteristics exerted substantial influence on ESA use. Policies to discourage inappropriate use of cancer therapies are needed. J Clin Oncol 29:3408-3418. (C) 2011 by American Society of Clinical Oncology
引用
收藏
页码:3408 / 3418
页数:11
相关论文
共 37 条
  • [1] Use of erythropoietin in cancer patients: Assessment of oncologists' practice patterns in the United States and other countries
    Adams, JR
    Elting, LS
    Lyman, GH
    George, JN
    Lembersky, BC
    Armitage, JO
    Demetri, GD
    Bennett, CL
    [J]. AMERICAN JOURNAL OF MEDICINE, 2004, 116 (01) : 28 - 34
  • [2] [Anonymous], INT CLASS DIS 9 REV
  • [3] Bennett CL, 2010, ONCOLOGY-NY, V24, P260
  • [4] Use of hematopoietic colony-stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines
    Bennett, CL
    Weeks, JA
    Somerfield, MR
    Feinglass, J
    Smith, TJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3676 - 3681
  • [5] Surgeon volume and operative mortality in the United States
    Birkmeyer, JD
    Stukel, TA
    Siewers, AE
    Goodney, PP
    Wennberg, DE
    Lucas, FL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) : 2117 - 2127
  • [6] Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data
    Bohlius, Julia
    Schmidlin, Kurt
    Brillant, Corinne
    Schwarzer, Guido
    Trelle, Sven
    Seidenfeld, Jerome
    Zwahlen, Marcel
    Clarke, Mike J.
    Weingart, Olaf
    Kluge, Sabine
    Piper, Margaret
    Napoli, Maryann
    Rades, Dirk
    Steensma, David
    Djulbegovic, Benjamin
    Fey, Martin F.
    Ray-Coquard, Isabelle
    Moebus, Volker
    Thomas, Gillian
    Untch, Michael
    Schumacher, Martin
    Egger, Matthias
    Engert, Andreas
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):
  • [7] Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
    Bohlius, Julia
    Schmidlin, Kurt
    Brillant, Corinne
    Schwarzer, Guido
    Trelle, Sven
    Seidenfeld, Jerome
    Zwahlen, Marcel
    Clarke, Michael
    Weingart, Olaf
    Kluge, Sabine
    Piper, Margaret
    Rades, Dirk
    Steensma, David P.
    Djulbegovic, Benjamin
    Fey, Martin F.
    Ray-Coquard, Isabelle
    Machtay, Mitchell
    Moebus, Volker
    Thomas, Gillian
    Untch, Michael
    Schumacher, Martin
    Egger, Matthias
    Engert, Andreas
    [J]. LANCET, 2009, 373 (9674) : 1532 - 1542
  • [8] EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update
    Bokemeyer, C.
    Aapro, M. S.
    Courdi, A.
    Foubert, J.
    Link, H.
    Osterborg, A.
    Repetto, L.
    Soubeyran, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (02) : 258 - 270
  • [9] EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
    Bokemeyer, C
    Aapro, MS
    Courdi, A
    Foubert, J
    Link, H
    Österborg, A
    Repetto, L
    Soubeyran, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) : 2201 - 2216
  • [10] ASSESSING ILLNESS SEVERITY - DOES CLINICAL JUDGMENT WORK
    CHARLSON, ME
    SAX, FL
    MACKENZIE, CR
    FIELDS, SD
    BRAHAM, RL
    DOUGLAS, RG
    [J]. JOURNAL OF CHRONIC DISEASES, 1986, 39 (06): : 439 - 452